Form 4: Venrock Funds Plan KalVista Stock Sales

Venrock Healthcare Capital Partners and affiliated entities filed a Form 4 disclosing planned sales of over 214,000 shares of KalVista Pharmaceuticals common stock in late March 2026 under a Rule 10b5-1 plan.

Summary

• Venrock Healthcare Capital Partners III, L.P. and affiliated entities, including VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Bong Koh, and Nimish Shah, filed a Form 4.
• The reporting persons are identified as Directors and 10% Owners of KalVista Pharmaceuticals, Inc. (KALV).
• The filing indicates planned dispositions of common stock under a Rule 10b5-1(c) contract, instruction, or written plan.
• A total of 214,631 shares of common stock are planned to be sold across multiple transactions on March 25 and March 26, 2026.
• The planned sales are at weighted average prices ranging from $16.95 to $19.12 per share.
• Following these planned transactions, the beneficial ownership of the reporting persons will decrease from an estimated 5,303,985 shares to 5,089,354 shares.
• The beneficial ownership is indirect, held by various funds managed by the Venrock entities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sales are pre-planned under a 10b5-1 plan, the reduction of a significant institutional investor's stake typically indicates a less bullish outlook or a strategic portfolio adjustment.

Negatives

• A significant institutional investor and 10% owner, Venrock Healthcare Capital Partners and its affiliates, plans to reduce its stake in KalVista Pharmaceuticals by 214,631 shares.
• The planned sales are at prices ranging from $16.95 to $19.12 per share.
• This reduction in ownership by a major holder, even if pre-planned, could be perceived negatively by the market, potentially signaling a less optimistic long-term outlook or a strategic portfolio rebalancing.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding KalVista Pharmaceuticals' operational or financial performance, focusing solely on planned insider transactions.

Industry Context

StockSavvy.ai notes that insider selling by a significant institutional investor like Venrock, even under a Rule 10b5-1 plan, can sometimes signal a shift in their investment thesis or portfolio rebalancing. While 10b5-1 plans are often for diversification or liquidity, the market may still interpret a reduction in a major holder's stake as a cautious signal, potentially influencing investor sentiment towards KalVista Pharmaceuticals within the biotechnology sector.

Stakeholder Impact

• Shareholders may interpret the planned reduction in ownership by a major institutional investor as a negative signal, potentially leading to decreased investor confidence or downward pressure on the stock price.

Key Dates

Recommendation

While the planned sales by Venrock Healthcare Capital Partners and its affiliates are executed under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than an immediate reaction to new information, the reduction of a significant 10% owner's stake is generally a negative signal. However, without further context on Venrock's overall portfolio strategy or KalVista's specific developments, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance closely.

Keywords

KalVista Pharmaceuticals, KALV, Venrock, insider selling, Form 4, common stock, equity sales, 10b5-1 plan